UNSPSC 51412803: Etafenone hydrochloride

This classification denotes a beta-adrenergic agonist with the molecular formula C21H27NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NTS160XKGC, chemically known as l.g.11,457 but more generally known as etafenone hydrochloride, which bears US NIH Compound Identifier 3275. European Medicines Agency schedules Etafenone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01980MIG.

Most nations, for tariff and trade purposes, schedule etafenone hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, ETAFENONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Etafenone hydrochloride bears US NLM identifiers UMLS ID C0105278 and NCI Concept Code C95811. SMILES: CCN(CC)CCOC1CCCCC1C(=O)CCC2CCCCC2.CL.

UNSPSC 51412803 Etafenone hydrochloride, a Commodity code, encompasses emergency and specialty pharmaceutical supplies that state and local governments procure for fire rescue operations, public health programs, and cooperative purchasing consortia. Recent state and local solicitations under this code reveal procurement of advanced life support medications, generic pharmaceuticals, and over-the-counter products supplied through established wholesale and direct-to-manufacturer channels. Issuing bodies include municipal fire departments operating through city purchasing offices, state health and human services agencies, and multistate cooperative purchasing alliances that coordinate procurement across member jurisdictions. The scope of work spans sealed-bid acquisition of specific medication line items with strict expiration and quality-assurance requirements, manufacturer direct-supply arrangements through pharmacy benefit programs, and generic pharmaceutical master agreements distributed via authorized wholesalers.

Recent activity concentrates in Florida and Minnesota, with multistate implications through cooperative purchasing vehicles. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) for Advanced Life Support Medications to be used by Tampa Fire Rescue on April 24, 2026, with a due date of April 8, 2026; the solicitation specified four medication line items totaling approximately 3,630 units with an estimated contract value of $40,000 and included a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP for generic multi-source pharmaceuticals and OTC products (posted January 20, 2026, due March 26, 2026) with participation from Oregon and other member states; awarded vendors supply products through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, with contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, indicating forward movement toward alternative supply-chain models.